1. Home
  2. CRVL vs AKRO Comparison

CRVL vs AKRO Comparison

Compare CRVL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVL
  • AKRO
  • Stock Information
  • Founded
  • CRVL 1987
  • AKRO 2017
  • Country
  • CRVL United States
  • AKRO United States
  • Employees
  • CRVL N/A
  • AKRO N/A
  • Industry
  • CRVL Specialty Insurers
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRVL Finance
  • AKRO Health Care
  • Exchange
  • CRVL Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • CRVL 4.6B
  • AKRO 3.9B
  • IPO Year
  • CRVL 1991
  • AKRO 2019
  • Fundamental
  • Price
  • CRVL $87.64
  • AKRO $49.56
  • Analyst Decision
  • CRVL
  • AKRO Strong Buy
  • Analyst Count
  • CRVL 0
  • AKRO 7
  • Target Price
  • CRVL N/A
  • AKRO $81.57
  • AVG Volume (30 Days)
  • CRVL 161.6K
  • AKRO 926.0K
  • Earning Date
  • CRVL 08-05-2025
  • AKRO 08-15-2025
  • Dividend Yield
  • CRVL N/A
  • AKRO N/A
  • EPS Growth
  • CRVL 28.38
  • AKRO N/A
  • EPS
  • CRVL 1.93
  • AKRO N/A
  • Revenue
  • CRVL $918,578,000.00
  • AKRO N/A
  • Revenue This Year
  • CRVL N/A
  • AKRO N/A
  • Revenue Next Year
  • CRVL N/A
  • AKRO N/A
  • P/E Ratio
  • CRVL $44.83
  • AKRO N/A
  • Revenue Growth
  • CRVL 12.46
  • AKRO N/A
  • 52 Week Low
  • CRVL $86.14
  • AKRO $21.34
  • 52 Week High
  • CRVL $128.61
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • CRVL 28.61
  • AKRO 45.71
  • Support Level
  • CRVL $86.14
  • AKRO $47.34
  • Resistance Level
  • CRVL $89.64
  • AKRO $49.92
  • Average True Range (ATR)
  • CRVL 2.78
  • AKRO 1.83
  • MACD
  • CRVL -0.18
  • AKRO -0.28
  • Stochastic Oscillator
  • CRVL 11.90
  • AKRO 32.71

About CRVL CorVel Corp.

CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: